In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

A United States-based Nigerian doctoral researcher in systems biology and immunology, Prosper Chukwuemeka, is advancing cancer research by combining computational tools with biology.

Breast cancer is the most prevalent malignancy among women worldwide. Despite significant advances in treatment, it remains one of the leading causes of female mortality. The inability to effectively ...

Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 ...

These proteins, called MDM2 and MDMX, become overactive in cancer and break down p53. Researchers have developed drugs to block MDM2 or MDMX, but targeting just one of these proteins is often not ...

Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.

Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study ...

Cutaneous melanoma can be a most challenging neoplasm of high lethality, in part due to its extreme heterogeneity and characteristic aggressive and invasive nature. Indeed, its moniker ‘the great ...

Successful treatment decisions in cancer depend on the accurate assessment of patient risk. To improve our understanding of the molecular alterations that underlie deadly malignancies, we analyzed the ...